MRM Health has appointed Hans-Jürgen Wörle to join the Board as an Independent Director. Wörle brings substantial M&A and investor-side experience across multiple acquisitions, in-licensing transactions and R&D collaborations.
Wörle is a highly accomplished, board-certified internist with longstanding experience in gastrointestinal diseases, as well as an endocrinologist and diabetologist, with senior R&D executive expertise across the entire drug development continuum.
Wörle previously served as Global Vice President Medicine at Boehringer Ingelheim, where he drove the development and global success of major diabetes therapies and secured the first-ever FDA cardiovascular-mortality claim for a diabetes medicine.
More recently, he was Chief Scientific and Medical Officer at Nestlé Health Science, where he was instrumental in transforming the organisation into a science-driven healthcare business, played a critical role in the development and successful commercial transaction of Vowst, the first FDA-approved oral microbiome therapy, and contributed to several landmark deals and product launches.
Wörle said: “The microbiome field has moved from promise to proof, and the question now is which programmes can be developed with the rigour and discipline that regulators and patients require. Having helped bring the first approved oral microbiome therapy through development, I see in MRM Health’s differentiated CORAL platform and promising MH002 clinical data in inflammatory bowel diseases the combination of science and execution that defines the next generation. I believe MH002 has great potential to address a major unmet medical need and am joining the team to help translate this into clinical reality for patients.”
Sam Possemiers, CEO of MRM Health, commented: “MRM Health is entering a pivotal phase, with MH002 advancing into phase 2b clinical development and significant momentum across the business. The appointment of Hans-Jürgen significantly strengthens our Board with a proven leader. This Board has been assembled to support MRM Health as we advance MH002 through phase 2b, prepare for late-stage development and position the Company for its next key milestones.”